Filing Flows › Xeris Biopharma Holdings (XERS) › Q2 2026 › vs Q2 2025
Xeris Biopharma Holdings (XERS) Q2 2026 vs Q2 2025 (year over year)
Xeris Biopharma Holdings's revenue rose $20.6M (+29%) from $71.5M in Q2 2025 to $92.1M in Q2 2026. The biggest changes: Product revenue, net +$24.6M (+37%); Royalty, contract and other revenue −$2.7M (-71%).
Xeris Biopharma Holdings, Q2 2026: revenue $92.1M (+29% year over year), operating margin 5.6%, net loss $31.1M, operating cash flow $8.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Recorlev | $56.8M | $31.4M | $25.3M | +81% |
| Gvoke | $22.5M | $23.5M | −$918K | -4% |
| Keveyis | $11.7M | $11.5M | $190K | +2% |
| Product revenue, net | $91.0M | $66.4M | $24.6M | +37% |
| Royalty, contract and other revenue | $1.1M | $3.8M | −$2.7M | -71% |
| Revenue | $92.1M | $71.5M | $20.6M | +29% |
| Net loss | $31.1M | $1.9M | $29.2M | 16× |
| Costs & expenses | $123M | $73.5M | $49.7M | +68% |
| Operating costs | $86.9M | $67.1M | $19.9M | +30% |
| Interest & other, net | $36.3M | $6.4M | $29.9M | +466% |
| Cost of revenue | $12.5M | $11.9M | $614K | +5% |
| Research & development | $10.7M | $8.1M | $2.6M | +32% |
| SG&A | $61.0M | $44.4M | $16.6M | +37% |
| Other operating costs | $2.7M | $2.7M | $0 | 0% |
| Operating cash sources | $39.4M | $2.1M | $37.3M | 19× |
| Depreciation & amortization | $323K | $325K | −$2K | -0.6% |
| Share-based compensation | $11.1M | $5.0M | $6.1M | +121% |
| Working capital & other | $28.0M | −$3.2M | $31.2M | — |
| Net loss absorbed | $31.1M | $1.9M | $29.2M | 16× |
| Operating cash flow | $8.3M | $182K | $8.1M | 45× |
Questions
How much did Xeris Biopharma Holdings's revenue grow year over year in Q2 2026?
Xeris Biopharma Holdings's revenue rose $20.6M (+29%) from $71.5M in Q2 2025 to $92.1M in Q2 2026.
What drove Xeris Biopharma Holdings's revenue change in Q2 2026?
Product revenue, net +$24.6M (+37%); Royalty, contract and other revenue −$2.7M (-71%).